Georg Pall1. 1. Department of Internal Medicine, Hematology/Oncology, University Hospital Innsbruck, Innsbruck, Austria.
Abstract
PURPOSE OF REVIEW: Crizotinib now is accepted as the standard first-line treatment of ALK-rearranged lung adenocarcinomas. To overcome the problem of crizotinib resistance, second-generation ALK inhibitors are in development. The aim of this review is to give an overview on the mechanisms behind crizotinib resistance and on the preclinical background and clinical development of these compounds. RECENT FINDINGS: Based on phase I/II data, ceritinib has gained accelerated FDA approval for the treatment of crizotinib-resistant ALK-rearranged lung cancer. The clinical development of alectinib has already reached phase III. With AP26113, ASP3026, TSR-011, X-396 and different heat shock protein 90 inhibitors, several other compounds led to promising early trial results. The toxicity profile of these drugs seems manageable, although side-effects still require attention and optimized supportive care. SUMMARY: Second-generation ALK inhibitors have arrived as part of our daily clinical practice. Challenges for the future will be to find the optimal place for these new drugs within the treatment algorithms. To reach this goal, careful trial design with special emphasis on genetically defined, homogeneous patient populations is imperative.
PURPOSE OF REVIEW: Crizotinib now is accepted as the standard first-line treatment of ALK-rearranged lung adenocarcinomas. To overcome the problem of crizotinib resistance, second-generation ALK inhibitors are in development. The aim of this review is to give an overview on the mechanisms behind crizotinib resistance and on the preclinical background and clinical development of these compounds. RECENT FINDINGS: Based on phase I/II data, ceritinib has gained accelerated FDA approval for the treatment of crizotinib-resistant ALK-rearranged lung cancer. The clinical development of alectinib has already reached phase III. With AP26113, ASP3026, TSR-011, X-396 and different heat shock protein 90 inhibitors, several other compounds led to promising early trial results. The toxicity profile of these drugs seems manageable, although side-effects still require attention and optimized supportive care. SUMMARY: Second-generation ALK inhibitors have arrived as part of our daily clinical practice. Challenges for the future will be to find the optimal place for these new drugs within the treatment algorithms. To reach this goal, careful trial design with special emphasis on genetically defined, homogeneous patient populations is imperative.
Authors: Shana Claeys; Geertrui Denecker; Kaat Durinck; Bieke Decaesteker; Liselot M Mus; Siebe Loontiens; Suzanne Vanhauwaert; Kristina Althoff; Caroline Wigerup; Daniel Bexell; Emmy Dolman; Kai-Oliver Henrich; Lea Wehrmann; Ellen M Westerhout; Jean-Baptiste Demoulin; Candy Kumps; Tom Van Maerken; Genevieve Laureys; Christophe Van Neste; Bram De Wilde; Olivier De Wever; Frank Westermann; Rogier Versteeg; Jan J Molenaar; Sven Påhlman; Johannes H Schulte; Katleen De Preter; Frank Speleman Journal: Oncogene Date: 2018-12-11 Impact factor: 9.867
Authors: Monica Ceccon; Maria Elena Boggio Merlo; Luca Mologni; Teresa Poggio; Lydia M Varesio; Matteo Menotti; Silvia Bombelli; Roberta Rigolio; Andrea D Manazza; Filomena Di Giacomo; Chiara Ambrogio; Giovanni Giudici; Cesare Casati; Cristina Mastini; Mara Compagno; Suzanne D Turner; Carlo Gambacorti-Passerini; Roberto Chiarle; Claudia Voena Journal: Oncogene Date: 2015-12-14 Impact factor: 9.867
Authors: Ali Saber; Anthonie J van der Wekken; Klaas Kok; M Martijn Terpstra; Lisette J Bosman; Mirjam F Mastik; Wim Timens; Ed Schuuring; T Jeroen N Hiltermann; Harry J M Groen; Anke van den Berg Journal: PLoS One Date: 2016-04-05 Impact factor: 3.240
Authors: Christian Ruiz; Stefan Kustermann; Elina Pietilae; Tatjana Vlajnic; Betty Baschiera; Leila Arabi; Thomas Lorber; Martin Oeggerli; Spasenija Savic; Ellen Obermann; Thomas Singer; Sacha I Rothschild; Alfred Zippelius; Adrian B Roth; Lukas Bubendorf Journal: PLoS One Date: 2016-08-22 Impact factor: 3.240